Adicet Bio
Develops off-the-shelf gamma delta CAR-T cell therapies for autoimmune disease and cancer.
$9.06
After-hours close+0.02 (+0.17%)
At close$9.05(+0.39%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 67.93%6.35M sharesInsiders 0.32%29.6K sharesOther 31.75%2.97M shares
Shares outstanding 9.35M · Float 8.20M · 87.8% free float
Institutions13F, as of Mar 31, 2026
49 holders · 6.35M shares · 13 new positions · 25 increased · 8 reduced · 13 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 1.18M | 12.65% | +234.4K | May 15, 2026 |
| Orbimed Advisors LLC | 1.03M | 11.00% | 0 | May 15, 2026 |
| Franklin Resources Inc | 626.6K | 6.70% | 0 | May 13, 2026 |
| Citadel Advisors LLC | 381.8K | 4.08% | +274.0K | May 15, 2026 |
| Vanguard Capital Management LLC | 336.5K | 3.60% | +336.5Knew | May 15, 2026 |
| Woodline Partners LP | 313.1K | 3.35% | −311.9K | May 15, 2026 |
| Adage Capital Partners GP, L.L.C. | 274.4K | 2.94% | 0 | May 15, 2026 |
| Prosight Management, LP | 250.2K | 2.68% | 0 | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P. | 12.30% | 1.18M | 13G | Apr 13, 2026 ↗ |
| Tang Capital Management, LLC | 9.90% | 13G | May 15, 2025 ↗ | |
| Orbimed Advisors LLCincl. Orbimed Israel Biofund GP Limited Partnership, Orbimed Israel GP Ltd. +5 more | 8.80% | 844.8K | 13D | Apr 10, 2026 ↗ |
| Franklin Resources, Inc. | 6.50% | 626.6K | 13G | Jan 29, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 10 percent owner | 932.6K | 9.98% | Apr 29, 2026 |
| Chen Schor | director, officer: President & CEO | 6.8K | 0.07% | Jan 27, 2026 |
| Lloyd Klickstein | director | 6.8K | 0.07% | Jun 13, 2025 |
| Brian Nicholas Harvey | officer: Chief Financial Officer | 5.1K | 0.06% | Jan 27, 2026 |
| Don Healey | officer: Chief Technology Officer | 3.5K | 0.04% | Jan 27, 2026 |
| Blake Aftab | officer: Chief Scientific Officer | 3.0K | 0.03% | Jan 27, 2026 |
| Steve Dubin | director | 1.4K | 0.02% | Jun 13, 2025 |
| Jeffrey Chodakewitz | director | 1.1K | 0.01% | Jun 13, 2025 |
| Andrew Sinclair | director | 1.1K | 0.01% | Jun 13, 2025 |
| Katie Peng | director | 738 | 0.01% | Jun 13, 2025 |
2 ten-percent owners hold 951.6K shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 13 people have not refiled in the last 18 months (136.1K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Feb 18, 2026 | Ra Capital Management, L.P.10 percent owner | Purchase | 74,577 | $7.04 | 1,033,605 |
| Feb 19, 2026 | Ra Capital Management, L.P.10 percent owner | Purchase | 74,268 | $7.21 | 1,107,873 |
| Feb 20, 2026 | Ra Capital Management, L.P.10 percent owner | Purchase | 74,751 | $7.27 | 1,182,624 |
| Apr 8, 2026 | Orbimed Advisors LLC10 percent owner | Sale · 2 lots | 72,939 | $6.42 | 0 |
| Apr 7, 2026 | Orbimed Advisors LLC10 percent owner | Sale · 2 lots | 31,719 | $6.52 | 32,523 |
| Oct 8, 2025 | Orbimed Advisors LLC10 percent owner | Purchase · 2 lots | 5,000,000 | $1.00 | 9,026,359 |
CongressHouse and Senate disclosures
Not reported.